Today’s non-invasive diagnostic tests provide little explanation of chest pain, leading many patients to unnecessary invasive testing.
In fact, more than half of patients who undergo these invasive tests have no significant blockage.1
1 Patel, et al., N Engl J Med 2010; 362: 886-95.
2 / 3 Douglas et al. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFRCT: outcome and resource impacts study. Eur Heart J. 2015;36(47):3359-67.
4 Douglas et al. Presented at the American College of Cardiology 65th Annual Scientific Session, 2016.
5 Data on file. In the PLATFORM Trial, the mean one-year per-patient cost for the usual care strategy was $12,145 compared to the $8,127 cost for the HeartFlow-guided strategy, a cost reduction of 33 percent. Not reported in the study results, mean costs remained 26 percent lower among the HeartFlow-guided patients than among usual care patients ($9,036 vs. $12,145, p<0.0001) when factoring in the $1,500 cost of the HeartFlow Analysis.
6 Hlatky et al. Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography: PLATFORM. J Am Coll Cardiol. 2015;66(21):2315-23.